Dr. Rainer Strohmenger

Dr. Rainer Strohmenger

Managing Partner

Great things in business are never done by one person. They're done by a team of people.

— Steve Jobs


With over 25 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 23 years of investment activity have involved financing of some of the most successful European biotech, medtech, diagnostics and digital health companies.

In the late 1990s he co-managed Wellington’s investment in Swiss biotech player Actelion, which became the most successful venture-backed biopharmaceutical company in Europe and was acquired in 2017 by Johnson & Johnson for US$ 30 billion. He was also responsible for the investments in Grandis (acquired by Novartis), Wavelight (acquired by Alcon), NoemaLife (acquired by Dedalus Group), mtm laboratories (acquired by Roche), immatics (Nasdaq: IMTX), Oxford Immunotec (NASDAQ: OXFD), invendo medical (acquired by Ambu), Genkyotex (acquired by Calliditas) as well as Definiens (acquired by Medimmune).

Prior to joining Wellington Partners, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany.

Rainer holds a M.D. in medicine as well as a M.Sc. in economics, both from Ludwig-Maximilians-University in Munich, Germany, and was trained at the Entrepreneurship Center of the MIT, Boston, USA.

He represents Wellington Partners on the VC Council of Invest Europe and is a Member of the Senate at the German Association of Small and Medium-sized Businesses (BVMW).